image
Healthcare - Medical - Devices - NASDAQ - US
$ 10.01
-2.15 %
$ 1.26 B
Market Cap
-8.86
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ATEC stock under the worst case scenario is HIDDEN Compared to the current market price of 10 USD, Alphatec Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ATEC stock under the base case scenario is HIDDEN Compared to the current market price of 10 USD, Alphatec Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ATEC stock under the best case scenario is HIDDEN Compared to the current market price of 10 USD, Alphatec Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ATEC

image
$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
424 M REVENUE
-12.03%
-136 M OPERATING INCOME
21.47%
-162 M NET INCOME
100.00%
-44.7 M OPERATING CASH FLOW
43.11%
-93.1 M INVESTING CASH FLOW
34.40%
56.2 M FINANCING CASH FLOW
-84.25%
122 M REVENUE
-19.33%
-23.8 M OPERATING INCOME
22.36%
-33.3 M NET INCOME
15.86%
10.5 M OPERATING CASH FLOW
296.99%
-3.75 M INVESTING CASH FLOW
81.16%
50.6 M FINANCING CASH FLOW
656.53%
Balance Sheet Alphatec Holdings, Inc.
image
Current Assets 417 M
Cash & Short-Term Investments 139 M
Receivables 83 M
Other Current Assets 196 M
Non-Current Assets 358 M
Long-Term Investments 0
PP&E 191 M
Other Non-Current Assets 167 M
17.90 %10.70 %25.21 %24.63 %21.56 %Total Assets$775.7m
Current Liabilities 153 M
Accounts Payable 53 M
Short-Term Debt 8.11 M
Other Current Liabilities 91.9 M
Non-Current Liabilities 637 M
Long-Term Debt 602 M
Other Non-Current Liabilities 35 M
6.71 %11.64 %76.19 %4.43 %Total Liabilities$789.9m
EFFICIENCY
Earnings Waterfall Alphatec Holdings, Inc.
image
Revenue 424 M
Cost Of Revenue 0
Gross Profit 424 M
Operating Expenses 560 M
Operating Income -136 M
Other Expenses 26 M
Net Income -162 M
500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)424m0424m(560m)(136m)(26m)(162m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-32.10% OPERATING MARGIN
-32.10%
-38.21% NET MARGIN
-38.21%
1144.21% ROE
1144.21%
-20.90% ROA
-20.90%
-21.59% ROIC
-21.59%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alphatec Holdings, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -162 M
Depreciation & Amortization 0
Capital Expenditures -93.1 M
Stock-Based Compensation 0
Change in Working Capital -67.3 M
Others -44.7 M
Free Cash Flow -138 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alphatec Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for ATEC of $16.5 , with forecasts ranging from a low of $8 to a high of $19 .
ATEC Lowest Price Target Wall Street Target
8 USD -20.08%
ATEC Average Price Target Wall Street Target
16.5 USD 64.84%
ATEC Highest Price Target Wall Street Target
19 USD 89.81%
Price
Max Price Target
Min Price Target
Average Price Target
202018181616141412121010886644May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Alphatec Holdings, Inc.
image
Sold
0-3 MONTHS
6.27 M USD 5
3-6 MONTHS
2.23 M USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.03 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.15 M USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Alphatec Holdings: Business Has Reached An Inflection Point - Buy The Dip In recent years, Alphatec Holdings or "ATEC" has outperformed sales expectations on a regular basis and successfully taken share in the $8 billion U.S. spinal disorder treatment market. The company continues to benefit from M&A-related disruptions at key competitors, which has created opportunities for ATEC to grab additional market share. Following years of elevated cash usage, the company managed to generate free cash flow in the final quarter of 2024. seekingalpha.com - 1 month ago
ATEC Prices Upsized $350.0 Million Convertible Senior Notes Offering CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the pricing of its offering of $350,000,000 aggregate principal amount of 0.75% convertible senior notes due 2030 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from t. businesswire.com - 1 month ago
Alphatec Holdings, Inc. (ATEC) Q4 2024 Earnings Call Transcript Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Pat Miles - Chairman and CEO Todd Koning - CFO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Vik Chopra - Wells Fargo Eric Anderson - TD Cowen Phillip Dantoin - Piper Sandler Matt Miksic - Barclays Caitlin Cronin - Canaccord Genuity Jason Wittes - ROTH David Saxon - Needham Kallum Titchmarsh - Morgan Stanley Operator Good afternoon, everyone, and welcome to the webcast of ATEC's Fourth Quarter Financial Results. We would like to remind everyone that participants on the call will make forward-looking statements. seekingalpha.com - 1 month ago
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates Alphatec (ATEC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.37 per share a year ago. zacks.com - 1 month ago
ATEC to Participate in Upcoming Conferences CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor conferences: The Canaccord Genuity Musculoskeletal Conference in San Diego, CA, on March 10 2025, with a fireside chat at 10:30am PT The Barclays Global Healthcare Conference in Miami, FL, on March 11, 2025, with a fireside chat at 3:00pm ET If available. businesswire.com - 1 month ago
Alphatec (ATEC) Moves 9.1% Higher: Will This Strength Last? Alphatec (ATEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 3 months ago
Wall Street Analysts Predict a 73.42% Upside in Alphatec (ATEC): Here's What You Should Know The consensus price target hints at a 73.4% upside potential for Alphatec (ATEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 3 months ago
ATEC to Present at the 2025 J.P. Morgan Healthcare Conference CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will present at the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA, at 5:15pm PT on January 15, 2025. The webcast and the presentation materials will be available on the Investor Relations Section of the Company's website. About ATEC ATEC, through its wholl. businesswire.com - 4 months ago
Alphatec Holdings, Inc. (ATEC) Q3 2024 Earnings Call Transcript Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Pat Miles - Chairman and CEO Todd Koning - CFO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Mathew Blackman - Stifel Matt Miksic - Barclays Matthew O'Brien - Piper Sandler Caitlin Cronin - Cannacord David Saxon - Needham Sean Lee - H.C. Wainwright Drew Ranieri - Morgan Stanley Operator Good afternoon, everyone. seekingalpha.com - 5 months ago
Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates Alphatec (ATEC) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.35 per share a year ago. zacks.com - 5 months ago
ATEC Reports Third Quarter 2024 Financial Results And Raises Full-Year Guidance CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2024, and recent corporate highlights. Third Quarter 2024 Financial Results   Quarter Ended September 30, 2024 Total revenue $151 million GAAP gross margin 68% Non-GAAP gross margin 69% GAAP operating expenses $136 million Non-GAAP operating expenses $114 mil. businesswire.com - 5 months ago
ATEC to Report Third Quarter Financial Results on October 30, 2024 CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2024 financial results on October 30, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the. businesswire.com - 6 months ago
8. Profile Summary

Alphatec Holdings, Inc. ATEC

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.26 B
Dividend Yield 0.00%
Description Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.
Contact 1950 Camino Vida Roble, Carlsbad, CA, 92008 https://www.atecspine.com
IPO Date June 12, 2006
Employees 867
Officers Dr. Luiz Pimenta Chief Medical Officer Mr. J. Todd Koning Executive Vice President & Chief Financial Officer Mr. Ali Shorooghi Senior Vice President of Marketing Mr. Tyson Eliot Marshall General Counsel & Corporate Secretary Mr. Jonathan Allen Executive Vice President of Commercial Operations Mr. David P. Sponsel Executive Vice President of Sales Mr. Scott Lish Chief Operating Officer Mr. Joseph Walland Senior Vice President of Global Imaging Solutions Mr. Patrick S. Miles Executive Chairman, Chief Executive Officer & President Mr. Craig E. Hunsaker Executive Vice President of People and Culture